ArticleScience advances2019
Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant
Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 99 citations in OpenAlex.
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Genomic characterization and global lineage-plasmid context of aOne health (Amsterdam, Netherlands) · 2026Article
- De Novo Multi-Mechanism Antimicrobial Peptide Design via Multimodal Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SET-M33 peptide as a selectiveMicrobiology spectrum · 2026Article
- Prevalence of multidrug resistant and ESBL producing Enterobacteriaceae among patients with urinary tract infections in Southwest Shewa, Ethiopia.BMC infectious diseases · 2026Article
- Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Biguanide-functionalized peptide mimics effectively combat drug-resistant ESKAPE pathogens and meningitis.Nature communications · 2025Article
- Novel antibacterial peptide HfAMP against methicillin-resistant Staphylococcus aureus.BMC microbiology · 2025Article
- Evaluation of LLM-generated peptide as foundation template for discovery of effective encrypted AMPs against clinical superbugs.Microbiology spectrum · 2025Article
- Cathelicidin AS-12W Derived from the Alligator sinensis and Its Antimicrobial Activity Against Drug-Resistant Gram-Negative Bacteria In Vitro and In Vivo.Probiotics and antimicrobial proteins · 2025Article
- Threat and Control ofFoods (Basel, Switzerland) · 2025Review
- The antimicrobial peptide Cec4 has therapeutic potential against clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Article
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- Self-assembling peptide with dual function of cell penetration and antibacterial as a nano weapon to combat intracellular bacteria.Science advances · 2025Article
- Structural and functional analysis of Escherichia coli membrane disruption by Ib-M peptides.PloS one · 2025Article
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Recent advances in the development of antimicrobial peptides against ESKAPE pathogens.Heliyon · 2024Review
- Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics againstScience advances · 2024Article
- Accelerating Antimicrobial Peptide Discovery for WHO Priority Pathogens through Predictive and Interpretable Machine Learning Models.ACS omega · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance is a public health concern that threatens to undermine decades of medical progress. ESKAPE pathogens cause most nosocomial infections, and are frequently resistant to carbapenem antibiotics, usually leaving tigecycline and colistin as the last treatment options. However, increasing tigecycline resistance and colistin's nephrotoxicity severely restrict use of these antibiotics. We have designed antimicrobial peptides using a maximum common subgraph approach. Our best peptide (Ω76) displayed high efficacy against carbapenem and tigecycline-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.